Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Replimune Group, Inc. is a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies to transform cancer treatment [4] - The company was founded in 2015 and is headquartered in Woburn, MA [4] - Replimune's proprietary RPx platform utilizes a potent HSV-1 backbone to maximize immunogenic cell death and induce a systemic anti-tumor immune response [4] Inducement Equity Awards - The company granted inducement equity awards to 10 newly hired non-executive employees as a material inducement for their employment [2] - The inducement awards consist of non-qualified stock options to purchase a total of 11,085 shares and restricted stock units representing 22,225 shares of common stock [2] - Each option has an exercise price of $12.29 per share, equal to the closing price on March 5, 2025, and has a 10-year term with vesting over four years [2][3] Vesting Schedule - 25% of the underlying shares from the options will vest on the one-year anniversary of the grant date, with the remainder vesting in monthly installments over the next three years [2] - The restricted stock units will vest in approximately four equal annual installments starting on February 15, 2026 [2] Compliance and Approval - The inducement awards were approved by the compensation committee of the company's board of directors under Nasdaq Listing Rule 5635(c)(4) [3] - Although granted outside of the company's 2018 Equity Incentive Plan, the terms and conditions of the awards are consistent with that plan [3]